NEW - Activaero's Clinical Trials

Now that the company is fully supported by external investors, Activaero is now in a position to begin its own clinical program. The goal is to deliver well-known medications to the lungs using the AKITA^® inhalation system and in turn, develop and market new therapeutic advances.

Acti-AICS-001:

A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects with Asthma Requiring Chronic Oral Corticosteroid Treatment

EudraCT Number: 2009-014640-11

status: finished

Acti-SCIPE-001

An Open-Label Randomized Pilot Trial to Evaluate Tolerability, Safety and Applicability of AKITA Inhaled Budesonide Suspension in Children aged 3-11 years with Mild to Moderate Asthma

EudraCT Nummer: 2010-023981-27

status: finished

Additional clinical studies are in preparation.

Clinical trials with
AKITA^® inhalation systems:

AKITA² APIXNEB^TM

AKITA^® JET

For clinical trials contact:

Activaero GmbH

Wohraer Straße 37, 35285 Gemünden/Wohra, Deutschland

Tel. +49 (0)6453 64 818-0
Fax +49 (0)6453 64 818-22
E-mail studien(at)activaero.de